FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer

Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the requirement for the development of more effective AR targeting therapies. A key mechanism of resistance to anti-androgens is through expression of constitutively active AR variants (AR-Vs) that...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Jones, Dominic, Wade, Mark, Nakjang, Sirintra, Chaytor, Lewis, Grey, James, Robson, Craig N., Gaughan, Luke
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4745762/
https://ncbi.nlm.nih.gov/pubmed/26336819
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items